A
2.06
0.17 (8.99%)
| Penutupan Terdahulu | 1.89 |
| Buka | 1.90 |
| Jumlah Dagangan | 938,515 |
| Purata Dagangan (3B) | 1,272,533 |
| Modal Pasaran | 201,741,152 |
| Harga / Jualan (P/S) | 2.71 |
| Harga / Buku (P/B) | 1.47 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -257.54% |
| Margin Operasi (TTM) | -301.32% |
| EPS Cair (TTM) | -1.71 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 68.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 29.12% |
| Nisbah Semasa (MRQ) | 3.29 |
| Aliran Tunai Operasi (OCF TTM) | -220.95 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -66.92 M |
| Pulangan Atas Aset (ROA TTM) | -19.25% |
| Pulangan Atas Ekuiti (ROE TTM) | -112.55% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Alector, Inc. | Menurun | Menurun |
AISkor Stockmoo
1.3
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.25 |
|
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 9.97% |
| % Dimiliki oleh Institusi | 96.64% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 35.00 (HC Wainwright & Co., 1,599.03%) | Beli |
| Median | 4.50 (118.45%) | |
| Rendah | 3.00 (Morgan Stanley, 45.63%) | Jual |
| Purata | 11.75 (470.39%) | |
| Jumlah | 2 Beli, 1 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 3.19 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Stifel | 16 Dec 2024 | 4.00 (94.17%) | Pegang | 1.98 |
| BTIG | 26 Nov 2024 | 5.00 (142.72%) | Beli | 2.57 |
| Morgan Stanley | 26 Nov 2024 | 3.00 (45.63%) | Jual | 2.57 |
| HC Wainwright & Co. | 07 Nov 2024 | 35.00 (1,599.03%) | Beli | 5.64 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Jan 2025 | Pengumuman | Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025 |
| 25 Nov 2024 | Pengumuman | Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update |
| 14 Nov 2024 | Pengumuman | Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital |
| 06 Nov 2024 | Pengumuman | Alector Reports Third Quarter 2024 Financial Results and Provides Business Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |